Froeding LP, Høgdall C, Kristensen E, et al. - Among patients with clinically stage IB-II unifocal vulva squamous cell carcinoma, tumor < 4 cm and no clinically doubtful groin nodes or distant metastases, who underwent sentinel node (SN)-procedure, researchers undertook this inquiry to assess the risk of recurrence as well as survival in SN- negative vulva cancer (VC) patients. They obtained nationwide data and registered that prospectively in the Danish Gynecologic Cancer Database from January 2011 to July 2017. A median follow-up of 30 months was performed, during which, one or more recurrences were reported in 23 of the 190 SN-negative patients (12.1%). The 3-year overall survival for SN-negative patients was estimated to be 84% and the estimated 3-year disease-specific survival (DSS) for these patients was 93%. In this largest prospective nationwide inquiry about SN-procedure in vulva cancer, the safety of the SN-procedure was corroborated in selected early-stage VC patients with a low isolated groin recurrence rate and a good DSS.